|Issuer:||TRAVERE THERAPEUTICS, INC. (TVTX)|
|Original Submission Date:|
REED ELIZABETH E
C/O TRAVERE THERAPEUTICS, INC.
3611 VALLEY CENTRE DR., SUITE 300 SAN DIEGO, CA 92130
|Title of Security||Transaction Date||2a. Deemed Execution Date||Transaction Code||Shares||Acquired or Disposed||Price per share||5. Amount of Securities Beneficially Owned Following Reported Transaction||6. Ownership Form Direct or Indirect||Nature of Indirect Ownership|
|Title of Derivative Security||Conversion or Exercise Price of Derivative Security||Transaction Date||Deemed Execution Date||Transaction Code||Number of Derivative Securities Acquired (A) or Disposed of (D)||Date Exercisable||Expiration Date||Title and Amount of Securities Underlying Derivative Security||Price of Derivative Security||Number of derivative Securities Beneficially Owned Following Reported Transaction(s)||Ownership Form: Direct (D) or Indirect (I)||Nature of Indirect Beneficial Ownership|
|f1||(1) on january 31, 2020, the reporting person was granted a performance restricted stock unit (prsu) grant covering 9,000 shares of the issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. on february 3, 2021, a portion of the prsus vested upon the issuer's confirmation of the satisfaction of a performance criterion related to the interim data read-out from the duplex study.|